Journal Basic Info

  • Impact Factor: 1.809**
  • H-Index: 6
  • ISSN: 2474-1655
  • DOI: 10.25107/2474-1655
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Anesthesiology and Pain Medicine
  •  Ophthalmology
  •  Chemotherapy
  •  Pneumonia
  •  Dermatology and Cosmetology
  •  Geriatric Medicine
  •  Gastric Cancer
  •  Cardiac Surgery

Abstract

Citation: Ann Clin Case Rep. 2022;7(1):2358.DOI: 10.25107/2474-1655.2358

Placebo-Controlled Clinical Study of Membrane-Free Stem Cell Extract in Dogs with Osteoarthritis

Kim YS2, Yoon MJ2, Lee SJ2 and Kim GS1*

1Research Institute of Life science and College of Veterinary Medicine, Gyeongsang National University, South Korea
2T-Stem Co Ltd, South Korea

*Correspondance to: Gon Sup Kim 

 PDF  Full Text Research Article | Open Access

Abstract:

Osteoarthritis (OA) is a chronic degenerative disease which commonly occurred in dogs. Although there are many treat options, they can only relieve symptoms, but not can modify the disease. Moreover, conventional treatment has limitations because of its adverse events. Therefore, it is necessary that development of Disease Modifying OA Drugs (DMOADs) with low adverse effects. To evaluate the effects of Membrane-Free Stem Cell Extract (MFSCE) on the clinical signs and cartilage regeneration of OA dogs. Thirty privately owned dogs with OA were separated into two groups; placebo treated group (n=6), MFSCE treated group (n=22). All dogs were injected MFSCE or placebo once a week for 4 weeks in intra-articular. To evaluate the symptoms, dogs and owners were visit hospital at day 0, 7, 14, 21, and 28. The effect of MFSCE on pain relief was evaluated using pain score and pain at palpation score. Both symptoms were improved in MFSCE treated group while no significant changes in placebo treated group after 4 weeks treatment. The effect of MFSCE on physical function improvement was evaluated using behavior score, standing score, walking score, lameness score, and weight bearing score. All symptoms were improved in MFSCE treated group while no significant changes in placebo treated group after 4 weeks treatment. The effects of MFSCE on joint structure were evaluated using radiographic score. Joint structure was improved in MFSCE treated group while no significant changes in placebo treated group after 4 weeks treatment. There were no changes on general symptoms, symptoms of lesion, adverse events or general symptoms that can be occurred by injection, hematological parameter, and urinal parameters. Overall, these results, MFSCE could be the first-in-class DMOAD.

Keywords:

Cite the Article:

Kim YS, Yoon MJ, Lee SJ, Kim GS. Placebo-Controlled Clinical Study of Membrane-Free Stem Cell Extract in Dogs with Osteoarthritis. Ann Clin Case Rep. 2022; 7: 2358..

Search Our Journal

Journal Indexed In

Articles in PubMed

Tocotrienols: Exciting Biological and Pharmacological Properties of Tocotrienols and other Naturally Occurring Compounds, Part I
 PubMed  PMC  PDF  Full Text
A New Minimally Invasive Procedure for Muscle, Back, Neck Pain and Radiculopathy - The Myofascial Nerve Block
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Adult-Onset, Obesity and Serious Insulin Resistance are New Characteristics for T1DM
 Abstract  PDF  Full Text
Thyroid Hormone Resistance Syndrome Caused by Heterozygous R338W Mutation in Thyroid Hormone Receptor β: Report of one Chinese Pedigree a in Southwest China
 Abstract  PDF  Full Text
View More...